Merck returns antifungal rights to Scynexis
Research Triangle Park, N.C. — Merck (NYSE: MRK)is returning all of the rights of an antifungal compound to Scynexis after the drug giant decided it did not want to pursue that compound anymore....
Please Log In to add a comment.
Best of TechWire Insider
- Two Toasters celebrates Inc. 5000 by paying it forward: A fundraiser for Girls Who Code
- Clinverse CEO: Pharma industry changes mean more business opportunities
- Prediction: Failure to pass crowdfunding, other economic development bills will hurt N.C.
- Inside Inc. 5000: Two Toasters' mobile apps deliver 579% growth
- Clinverse CEO: New venture funding to drive expansion, create new jobs
- Crowdfunding killed in NC; bill backer criticizes Senate strategy
- Exclusive: GroundFloor isn't moving to Atlanta due to NC crowdfunding impasse
- Exclusive: In-depth survey helps ChannelAdvisor plot next ecommerce moves
- Crowdfunding, solar, job recruitment at stake in legislative impasse
- New life for crowdfunding bill: House will review Monday